MorphoSys Completes Enrollment in MOR103 Phase 1b/2a Rheumatoid Arthritis Trial

MorphoSys AG /
MorphoSys Completes Enrollment in MOR103 Phase 1b/2a Rheumatoid Arthritis Trial
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.

Study Data Expected in Q3 2012

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today the
successful completion of patient enrollment in its phase 1b/2a clinical trial
evaluating MOR103, a HuCAL antibody targeting GM-CSF (granulocyte macrophage-
colony stimulating factor). 96 patients with active rheumatoid arthritis (RA)
have been randomized in the double-blind, placebo-controlled study at various
clinical centers in Europe to evaluate the safety and preliminary signs of
clinical activity of MOR103 when administered intravenously in multiple doses.
Data from the trial will become available in Q3 2012.

"Within the past months, MorphoSys´s entire proprietary portfolio has advanced
significantly, " commented Dr. Arndt Schottelius, Chief Development Officer of
MorphoSys AG. "We currently have four proprietary programs in clinical trials,
all of them targeting novel or better treatment options for severe diseases. We
are well on track to expect a whole range of exciting news from our own
development portfolio in the years to come. GM-CSF is strongly implicated in the
pathogenesis of inflammatory diseases, including rheumatoid arthritis. Data
generated with an antibody targeting the GM-CSF receptor last year provided
further clinical validation of the GM-CSF pathway in RA."

In addition to the RA study, MOR103 is currently being evaluated in two
additional clinical trials. Patient enrollment in a phase 1b dose-escalation
study in multiple sclerosis began in early 2012. A phase 1 pharmacokinetic study
in healthy volunteers to evaluate a subcutaneous formulation of MOR103 will
recruit the final cohort shortly. Subcutaneous injection represents a more
convenient route of administration for patients and the data will help guide
dosing regimens for future clinical trials for MOR103.

In total, MorphoSys currently has four proprietary clinical programs ongoing,
including MOR103 in RA and MS, as well as MOR202, a HuCAL antibody targeting
CD38, in multiple myeloma and MOR208, an Fc-enhanced humanized antibody
targeting CD19, in chronic lymphocytic leukemia and other B-cell malignancies.

About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic